What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ?

@inproceedings{Barosi2014WhatIT,
  title={What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ?},
  author={Giovanni Barosi and Valentina Poletto and Elisa Bonetti and Laura Villani and Paolo Catarsi and Gianluca Viarengo and Rita Campanelli and Margherita Massa and Vittorio Rosti},
  year={2014}
}
  • Giovanni Barosi, Valentina Poletto, +6 authors Vittorio Rosti
  • Published 2014
  • Medicine
  • Data from COMFORT-I and COMFORT-II trials indicate that the JAK1/JAK2 inhibitor ruxolitinib is effective in reducing splenomegaly and reversing symptoms in patients with MPN-associated MF (Verstovsek S. et al, NEJM 2012;366:799; Harrison C. et al. NEJM 2012;366:787). However, not all subjects in these studies needed therapy for splenomegaly according newly-reported criteria (Barosi et al, Leuk Res 2014;38:155). Moreover, splenomegaly response was defined as 35% reduction in spleen volume by… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv